Kwangdong Pharmaceutical Co. Ltd.

05/10/2022 | Press release | Distributed by Public on 05/10/2022 02:27

Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)

Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure)
※ The following are interim figures, and may be different from final data.
1. Details of business performance in KRW mn, %
Category Current term Previous term Changes over previous term(%) Same term of last year Changes over same term of last year (%)
('22.1Q) ('21.4Q) ('21.1Q)
Sales Current 312,247 360,769 -13.4 294,142 6.2
Cumulative 312,247 1,338,182 - 294,141 6.2
Operating income Current 8,962 12,312 -27.2 8,511 5.3
Cumulative 8,962 44,936 - 8,511 5.3
Net income from continuing operation before income tax Current 11,354 8,468 34.1 8,359 35.8
Cumulative 11,354 34,329 - 8,359 35.8
Net income Current 8,424 6,867 22.7 6,893 22.2
Cumulative 8,424 25,541 - 6,893 22.2
Net income attributable to shareholders of parent company Current 7,587 6,587 15.2 6,153 23.3
Cumulative 7,587 24,019 - 6,153 23.3
- - - - - -
2. Details of information release Information provider Kwangdong Finance Team
Information recipients Institutional Investors & Analysts
Date & time of information release After the fair disclosure
Title and place of event held -
3. Contact points (department/phone number) 02-6006-7777(7)
4. Other matters to be factored into investment decisions
- The above results are consolidated financial statements based on K-IFRS.

- The results above are currently under review by the external auditor and are subject to change. If the results change, the revised results will be disclosed.
※ Related disclosure -